Ribosomes make proteins. Techinno Health studied whether MitoIgnite® urolithin A affects new protein synthesis in stressed cells: in cell models including cardiac and liver cells, stress lowered the new-protein signal to about 20–35% of control, and 5 µM MitoIgnite® raised it about two- to three-fold. These are company-reported cell-culture results, not a human or clinical effect.
MitoIgnite® cell-model study
Reported 26 October 2026 · company-reported experiments
HPG-labelled new proteins (green) and nuclei (blue). A–B AC16 cells, C–D AML12 cells. Source: Techinno Health company-reported cell experiments.
What the data show, and what they do not
The figure measures new protein synthesis. On its own it does not establish which upstream mechanism caused the change, or demonstrate a health benefit in humans.
5 µM is a cell-culture concentration and a laboratory readout, not an oral dose or a clinical effect size.
Ribosome biogenesis, a change in ribosome-related gene expression, and a measured change in new protein synthesis are related observations, but they are not interchangeable results.
Patent status
PCT international patent application filed (October 2026) for a new urolithin A pathway mechanism: ribosome biogenesis and nascent protein synthesis. An application is not a granted patent. On this basis Techinno Health is China’s first urolithin A ingredient supplier with its own, self-researched efficacy patent. This refers to a PCT international patent application on a mechanism of urolithin A itself (October 2026), based on public patent records as of 12 November 2026.
How to cite this research
Techinno Health. Urolithin A and ribosomes: MitoIgnite® cell-model data (HPG-labelled new protein synthesis). Company-reported experiments, reported 26 October 2026. https://techinnohealth.com/en/ua/ribosome/Reported in a NutraIngredients paid partner feature by Techinno Health (26 October 2026); not an independent peer-reviewed publication. Read the NutraIngredients partner feature
Questions about urolithin A and ribosomes
Does urolithin A affect ribosomes?
The research question is whether urolithin A influences ribosome production and the synthesis of new proteins. Techinno Health’s MitoIgnite® data come from cell models; they do not establish a ribosome-mediated clinical benefit.
What did Techinno Health measure?
Cell models including AC16 cardiac and AML12 liver cells were exposed to oxidative stress, cell-cycle arrest or glycation-related stress, and HPG labelling measured newly made proteins. Stressed cells produced about 20–35% of the control signal; 5 µM MitoIgnite® urolithin A increased it about two- to three-fold relative to the stressed condition.
Is the ribosome mechanism patented?
A PCT international patent application for a new urolithin A pathway mechanism (ribosome biogenesis and nascent protein synthesis) was filed in October 2026. An application is not a granted patent.
How can I get the research information or a sample?
Contact Techinno Health with your intended application, target market, grade and requested quantity. We can discuss MitoIgnite® specifications, COAs, samples and research collaboration.